Latest news
Akebia Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Wed, 05 Aug 2026 22:03:49 GMTAKBA: Vafseo revenue and patient growth accelerated, offsetting AURYXIA declines amid robust pipeline progress - TradingViewTradingView · Wed, 05 Aug 2026 21:53:37 GMTAkebia Q2 2026 earnings: Vafseo growth did not offset Auryxia decline - TradingKeyTradingKey · Wed, 05 Aug 2026 21:21:47 GMTAKBA: Vafseo's strong growth offset Auryxia's decline, but total revenues and net income fell year-over-year - TradingViewTradingView · Wed, 05 Aug 2026 20:17:59 GMTAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila TimesThe Manila Times · Wed, 05 Aug 2026 20:09:33 GMTAkebia begins trial for three rare kidney diseases; data expected in 2027 - Stock TitanStock Titan · Wed, 05 Aug 2026 20:05:00 GMT